Department of Medicine
Faculty Profiles by Division

Division of Infectious Diseases

Faculty Profiles

[Return To Index page]
photo John W. Mellors, MD

Infectious Diseases

Distinguished Professor of Medicine

Endowed Chair for Global Elimination of HIV and AIDS

Email: jwm1@pitt.edu

Phone: 412-624-8512

Contact
Office: Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, PA 15261
 
Phone: 412-624-8512
Fax: 412-383-7982
E-mail: jwm1@pitt.edu
Administrative Assistant:
Trent Bauer
Address: Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, PA 15261
Email: tab320@pitt.edu
Phone: 412-383-9062
Fax: 412-648-8521
Administrative Assistant:
Lorraine Pollini
Address: Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, PA 15261
Email: Lmp27@pitt.edu
Phone: 412-383-0308
Fax: 412-383-7982
Education and Training
Education
BA, Dartmouth College, Hanover, NH, 1975
MD, Dartmouth Medical School, Hanover, NH, 1978
Training
Internship/Residency Training, Yale-New Haven Hospital, New Haven, CT, 1982
Infectious Diseases Fellowship Training, Yale University School of Medicine, New Haven, CT, 1985
Research Interest
Dr. Mellors led several studies with samples from the Multicenter AIDS Cohort Study (MACS) that established the critical relationship between plasma viremia (HIV-1 RNA) and HIV disease progression to AIDS and death in both acute and chronic HIV-1 infection. This work led to the universal use of plasma HIV-1 RNA and CD4+T-cell counts to estimate prognosis in HIV-1 infection and the optimal time to initiate antiretroviral therapy (ART). Dr. Mellors contributed to the development and testing of the first antiretroviral combinations that produced sustained suppression of viremia and recovery of CD4+T-cells that launched the current era of highly-effective ART.

Presently, Dr. Mellors' laboratory focuses on resistance to antiretroviral drugs used for treatment and HIV prevention and on mechanisms of HIV persistence and strategies to deplete the reservoirs that are the barrier to curing HIV infection. His work on HIV reservoirs showed that low-level viremia persists in most individuals on long-term suppressive ART, and that the level of residual viremia is predicted by the level of viremia before ART. Current work focuses on identifying agents to reverse HIV latency and to eliminate HIV infected cells. The impact of innovative therapies on HIV reservoirs is being studied in Phase I/II trials of histone deacetylase inhibitors, monoclonal antibodies to immune checkpoint ligands, monoclonal antibodies to HIV envelope glycoproteins, and TLR agonists.
Clinical Interest
Dr. Mellors is the Chief of the Infectious Diseases Division, a Distinguished Professor of Medicine, the Endowed Chair for Global Elimination of HIV and AIDS at University of Pittsburgh School of Medicine, and, Executive Director of the HIV/AIDS Program with the University of Pittsburgh Medical Center (UPMC). He has served as Chief of the Division of Infectious Diseases in the Department of Medicine for more than 20 years. Under his leadership, the Division has grown to 68 faculty and 198 staff, with $3 million in annual clinical revenue.

Dr. Mellors directs the primary care and clinical research activities in HIV/AIDS at UPMC Health System, providing care to over 1,700 HIV-infected individuals. His clinical interests are directed towards optimizing antiretroviral therapy of HIV infection, especially among individuals with antiretroviral drug resistance.
Educational Interest
Dr. Mellors is a tenured Professor of Medicine, Pathology, and Infectious Diseases and Microbiology, who has as a strong reputation as a knowledgeable and enthusiastic mentor and teacher at the University of Pittsburgh. He has lectured on “HIV-AIDS” in the Medical Microbiology course, “HIV-1 Antiviral Strategies” in the Retrovirology course of the Molecular Virology and Microbiology program and “HIV Cure” in the Prevention, Treatment, and Control of Global Infectious Diseases course within the Department of Infectious Diseases and Microbiology curriculum. Dr. Mellors has a long history of mentorship of fellows, residents and medical students. He has mentored six post-doctoral fellows, eleven pre-doctoral candidates, and serves on numerous dissertation committees.

Dr. Mellors offers trainees balanced guidance in the areas of research, authorship, grant writing, manuscript review and oral presentation based upon his extensive professional experience. Currently, one PhD student, a recipient of the Pitt AIDS Research Training (PART) Program award for pre-doctoral trainees, one Medical student, a recipient of two years of funding via the Medical Research Fellows Program awarded by the Howard Hughes Medical Institute (HHMI), and one post-doctoral associate, are benefiting from Dr. Mellors primary mentorship.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Mellors JW. Randomized trial of treatment interruption prior to optimized antiretroviral therapy for persons with drug-resistant HIV: 48 week virologic results of ACTG A5086. J Inf Dis 2006; 194:1309-18. J Inf Dis. 2006; 194: 1309-18.
McKinnon JE, Arribas JR, Pulido F, Delgado R, Mellors JW. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS. 2006; 20: 2331-5.
Sluis-Cremer N, Sheen CW, Zelina S, Torres PSAQ, Parikh UM, Mellors JW. Molecular mechanism by which K70E in HIV-1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2007; 51 PMCID: PMC1797654: 48-53.
Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Mellors JW. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007; 3(4) PMCID: PMC1847689: 46.
Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular Mechanisms of Bi-Directional Antagonism between K65R and Thymidine Analog Mutations in HIV-1 Reverse Transcriptase. AIDS. 2007; 21 PMID 17589186: 1405-1414.
Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, Munoz A. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell slope for progression to AIDS and death in untreated HIV-1 infection. JAMA. 2007; 297 (21): 2349-50.
Margolis DM, Mukherjee L, Fltecher CV, Hogg E, Ogata-Arakaki D, Petersen T, Russin D, Martinez A, Mellors JW for the ACTG 5165 Team. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenylate mofetil in drug-resistant HIV infection. AIDS. 2007; 21 PMID: 17885292: 2025-2032.
Brehm J, Koontz D, Meteer JD, Pithak V, Sluis-Cremer N, Mellors JW. Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase that Increase Resistance to 3'-Azido-3'-Dideoxythymidine. J Virol. 2007; 81 PMCID PMC1951314: 7852-9.
Abbas UL, Anderson RM, Mellors JW. Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings. PLoS ONE. 2007; 2(9) PMCID: PMC1975470: 875.
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Mellors JW for the ACTG A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. New Eng J Med. 2008; 358: 2095-2106.
Sponsored Research/Activities
Title: Pitt-Ohio State Clinical Trials Unit
Role: Principal Investigator
Funding Agency: National Institute of Health
Grant Number: RES XXX135506XXX
Start Year: 2020
End Year: 2027
Title: Gilead GS-US-380-4030 Laboratory Service Agreement
Role: Principal Investigator
Funding Agency: Gilead Sciences, Inc
Grant Number: RES
Start Year: 2020
End Year: 2025
Title: Single Copy HIV-1 RNA Measurements in Plasma BMT CTN Protocol #1903
Role: Principal Investigator
Funding Agency: National Marrow Donor Program
Grant Number: RES 1256658
Start Year: 2020
End Year: 2025
Title: HVTN AMP STUDY
Role: Principal Investigator
Funding Agency: Fred Hutchinson Cancer Research Center
Grant Number: RES
Start Year: 2020
End Year: 2021
Title: Pitt-Ohio State University Clinical Trials Unit ACTG administrative supplement
Role: Principal Investigator
Funding Agency: National Institute of Health
Grant Number: RES XXX135468XXX
Start Year: 2020
End Year: 2021
Title: Pitt-Ohio State Clinical Trials Unit Administrative Supplement
Role: Principal Investigator
Funding Agency: National Institute of Aging
Grant Number: UM1 AI069494
Start Year: 2020
End Year: 2020
Title: HPTN UNANTICIPATED COSTS
Role: Principal Investigator
Funding Agency: Family Health International
Grant Number: UM1 A1068619
Start Year: 2020
End Year: 2020
Title: Subaward No 1061687_14C Supplement
Role: Principal Investigator
Funding Agency: Beth Israel Deaconess
Grant Number: UM1
Start Year: 2019
End Year: 2020
Title: AIDS Malignancy Clinical Trials Consortium Study - HIV Malignancy Reservoir Analysis
Role: Principal Investigator
Funding Agency: Emmes Corporation/ National Cancer Institute
Grant Number: UM1
Start Year: 2019
End Year: 2020
Title: Comprehensive Assessment of Resistance Risk and Development of Policy Recommendations for Microbicide/PrEP Roll Out
Role: Principal Investigator
Funding Agency: United States Agency International Development
Start Year: 2015
End Year: 2020
Title: Bench to Bedside: Localizing Reservoirs of HIV Persistence in Lymphoid Tissue (Supplement)
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI069494
Start Year: 2013
End Year: 2020
Title: Pittsburgh HIV Mentored Training for Investigation of Co-morbidities and Cure (HIV MeTrICC)
Role: Co-Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: K12 HL143886
Start Year: 2018
End Year: 2023
Title: MTN Virology Core
Role: Co-Investigator
Funding Agency: Magee Womens Hospital/National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI106707
Start Year: 2014
End Year: 2020
Title: AIDS Clinical Trials Group - VSL
Role: Co-Investigator
Funding Agency: Brigham and Women's Hospital, Inc.
Grant Number: UM1 AI106701
Start Year: 2014
End Year: 2020
Title: LOC, ACTG, A5381
Role: Site Investigator
Funding Agency: University of California Los Angeles / National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2019
End Year: 2020
Notable Achievements
Chair, AIDS Clinical Trials Group (ACTG) HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG), 2011-2014
Recipient of National Institutes of Health National Cancer Institute Award of Merit, 2015
Endowed Chair for Global Elimination of HIV and AIDS, 2016